tradingkey.logo
tradingkey.logo

Transmedics Group Inc

TMDX
137.070USD
-0.500-0.36%
終値 01/09, 16:00ET15分遅れの株価
4.68B時価総額
50.64直近12ヶ月PER

Transmedics Group Inc

137.070
-0.500-0.36%

詳細情報 Transmedics Group Inc 企業名

TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

Transmedics Group Incの企業情報

企業コードTMDX
会社名Transmedics Group Inc
上場日May 02, 2019
最高経営責任者「CEO」Hassanein (Waleed H)
従業員数728
証券種類Ordinary Share
決算期末May 02
本社所在地200 Minuteman Road
都市ANDOVER
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号01810
電話番号19785520900
ウェブサイトhttps://www.transmedics.com/
企業コードTMDX
上場日May 02, 2019
最高経営責任者「CEO」Hassanein (Waleed H)

Transmedics Group Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-47529.00%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
177.21K
+2134.00%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
12.13K
--
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-5640.00%
Mr. Thomas James Gunderson
Mr. Thomas James Gunderson
Independent Director
Independent Director
4.06K
+2134.00%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
4.06K
+2134.00%
Ms. Stephanie Lovell
Ms. Stephanie Lovell
Independent Director
Independent Director
4.06K
+2134.00%
Mr. Gerardo Hernandez
Mr. Gerardo Hernandez
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
331.00
-15653.00%
Dr. Tamer I. Khayal, M.D.
Dr. Tamer I. Khayal, M.D.
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Edward M. Basile
Mr. Edward M. Basile
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Waleed H. Hassanein, M.D.
Dr. Waleed H. Hassanein, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
481.61K
-47529.00%
Mr. James R. Tobin
Mr. James R. Tobin
Independent Chairman of the Board
Independent Chairman of the Board
177.21K
+2134.00%
Dr. David Weill, M.D.
Dr. David Weill, M.D.
Independent Director
Independent Director
12.13K
--
Mr. Nicholas (Nick) Corcoran
Mr. Nicholas (Nick) Corcoran
Senior Vice President - Supply Chain and Operations
Senior Vice President - Supply Chain and Operations
7.04K
-5640.00%
Mr. Thomas James Gunderson
Mr. Thomas James Gunderson
Independent Director
Independent Director
4.06K
+2134.00%
Ms. Merilee Raines, CPA
Ms. Merilee Raines, CPA
Independent Director
Independent Director
4.06K
+2134.00%

収益内訳

通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
OCS Liver net revenue
107.94M
75.67%
OCS Heart net revenue
30.59M
21.44%
OCS Lung net revenue
4.11M
2.88%
地域別USD
会社名
収益
比率
United States
139.01M
97.46%
All other countries
3.63M
2.54%
事業別
地域別
事業別USD
会社名
収益
比率
OCS Liver net revenue
107.94M
75.67%
OCS Heart net revenue
30.59M
21.44%
OCS Lung net revenue
4.11M
2.88%

株主

更新時刻: Fri, Jan 9
更新時刻: Fri, Jan 9
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
13.86%
Fidelity Management & Research Company LLC
13.45%
The Vanguard Group, Inc.
10.53%
State Street Investment Management (US)
3.74%
Two Sigma Investments, LP
3.10%
他の
55.32%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
13.86%
Fidelity Management & Research Company LLC
13.45%
The Vanguard Group, Inc.
10.53%
State Street Investment Management (US)
3.74%
Two Sigma Investments, LP
3.10%
他の
55.32%
種類
株主統計
比率
Investment Advisor
72.11%
Investment Advisor/Hedge Fund
23.66%
Hedge Fund
7.08%
Research Firm
4.62%
Individual Investor
2.95%
Bank and Trust
2.15%
Pension Fund
1.35%
Sovereign Wealth Fund
0.18%
Insurance Company
0.10%

機関投資家保有株

更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
779
37.88M
110.86%
-5.14M
2025Q3
762
37.62M
110.09%
-8.17M
2025Q2
746
42.27M
124.01%
-2.30M
2025Q1
751
42.32M
125.08%
-2.32M
2024Q4
728
40.09M
119.11%
-642.74K
2024Q3
673
39.30M
117.10%
+1.37M
2024Q2
615
36.53M
110.85%
-3.27M
2024Q1
544
37.44M
113.97%
-4.28M
2023Q4
512
38.18M
116.94%
-3.46M
2023Q3
482
38.42M
117.77%
-240.92K
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
4.74M
13.86%
+9.44K
+0.20%
Sep 30, 2025
Fidelity Management & Research Company LLC
4.60M
13.45%
-31.07K
-0.67%
Sep 30, 2025
The Vanguard Group, Inc.
3.60M
10.53%
+9.16K
+0.26%
Sep 30, 2025
State Street Investment Management (US)
1.28M
3.74%
-9.47K
-0.73%
Sep 30, 2025
Two Sigma Investments, LP
1.06M
3.1%
+366.05K
+52.85%
Sep 30, 2025
Nomura Investment Management Business Trust
906.27K
2.65%
-45.84K
-4.81%
Sep 30, 2025
Geode Capital Management, L.L.C.
813.57K
2.38%
+8.92K
+1.11%
Sep 30, 2025
Driehaus Capital Management, LLC
738.16K
2.16%
-115.88K
-13.57%
Sep 30, 2025
Hood River Capital Management LLC
678.44K
1.99%
-1.41K
-0.21%
Sep 30, 2025
Emerald Advisers LLC
626.03K
1.83%
-68.95K
-9.92%
Sep 30, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Global X HealthTech ETF
4.75%
Clough Select Equity ETF
2.87%
Invesco S&P SmallCap Health Care ETF
2.75%
State Street SPDR S&P Health Care Equipment ETF
2.18%
Invesco S&P SmallCap 600 Pure Growth ETF
1.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
1.47%
iShares S&P Small-Cap 600 Growth ETF
0.63%
State Street SPDR S&P 600 Small Cap Growth ETF
0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
0.58%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.58%
詳細を見る
Global X HealthTech ETF
比率4.75%
Clough Select Equity ETF
比率2.87%
Invesco S&P SmallCap Health Care ETF
比率2.75%
State Street SPDR S&P Health Care Equipment ETF
比率2.18%
Invesco S&P SmallCap 600 Pure Growth ETF
比率1.54%
First Trust Nasdaq Lux Digi Health Solutions ETF
比率1.47%
iShares S&P Small-Cap 600 Growth ETF
比率0.63%
State Street SPDR S&P 600 Small Cap Growth ETF
比率0.61%
First Trust Multi-Manager Small Cap Opportunities ETF
比率0.58%
Vanguard S&P Small-Cap 600 Growth Index Fund
比率0.58%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
種類
比率
データなし
日付
種類
比率
データなし

よくある質問

Transmedics Group Incの上位5名の株主は誰ですか?

Transmedics Group Incの上位5名の株主は以下のとおりです。
BlackRock Institutional Trust Company, N.A.は4.74M株を保有しており、これは全体の13.86%に相当します。
Fidelity Management & Research Company LLCは4.60M株を保有しており、これは全体の13.45%に相当します。
The Vanguard Group, Inc.は3.60M株を保有しており、これは全体の10.53%に相当します。
State Street Investment Management (US)は1.28M株を保有しており、これは全体の3.74%に相当します。
Two Sigma Investments, LPは1.06M株を保有しており、これは全体の3.10%に相当します。

Transmedics Group Incの株主タイプ上位3種は何ですか?

Transmedics Group Incの株主タイプ上位3種は、
BlackRock Institutional Trust Company, N.A.
Fidelity Management & Research Company LLC
The Vanguard Group, Inc.

Transmedics Group Inc(TMDX)の株式を保有している機関の数はいくつですか?

2025Q4時点で、Transmedics Group Incの株式を保有している機関は779社あり、保有株式の総市場価値は約37.88Mで、全体の110.86%を占めています。2025Q3と比較して、機関の持ち株は0.77%増加しています。

Transmedics Group Incの最大の収益源は何ですか?

FY2025Q3において、OCS Liver net revenue部門がTransmedics Group Incにとって最大の収益を生み出しており、その金額は107.94Mで、全収益の75.67%を占めています。
KeyAI